ESMO Open

The Open Access journal of @myESMO dedicated to oncology research

[Paolo Tarantino @PTarantinoMD]

Primary results from BRIDGET ph2 trial presented by @drsarahsam and published in @ESMO_Open. Adding tucatinib to HP after an isolated intracranial PD led to impressively long PFS (59% free from PD or death at 18mo!!). Reasonable strategy from next Monday in TKI-naive patients.

[ESMO Open @ESMO_Open]

Addition of Tucatinib to Trastuzumab/Pertuzumab After Local Therapy for Isolated icPD in HER2+mBC: Primary Results of the Ph2 BRIDGET Trial in @ESMO_Open presented at #ESMO2026. Median icPFS not reached (mFUP 19.6 months), 46/47 pts alive @ data cut-off. https://t.co/I3itxyrV2a

[ESMO Open @ESMO_Open]

Ultra-sensitive MRD Assessment in Long-term Complete Responders to Anti-HER2 Therapy in HER2+ mBC: Initial Results from HER2-CR Study in @ESMO_Open presented at #ESMO2026. Most LTR remained ctDNA-; persistent ctDNA+ associated with subsequent PD. https://t.co/vP9j9px2AY

[ESMO Open @ESMO_Open]

Trastuzumab deruxtecan in patients with desmoplastic small round cell tumors (DSRCT): a retrospective analysis from the French Sarcoma Group in @ESMO_Open presented at #ESMO2026. Substantial activity (10/12,ORR 83%) across HER2 expression. https://t.co/1Fhcr8mPEJ

[ESMO Open @ESMO_Open]

Liquid biopsy-guided molecular hyperselection for anti-EGFR rechallenge therapy in refractory metastatic colorectal cancer: a pooled analysis of 4 trials in @ESMO_Open presented at #ESMO26. LB-based hyperselection of pts leads to better PFS & OS. https://t.co/TaC60t7nQF

[ESMO Open @ESMO_Open]

When OS Is Not Enough: The Emerging Need for Context-Sensitive Endpoint Frameworks in Oncology in @ESMO_Open presented at #ESMO2026. Context-sensitive frameworks are needed when OS is immature/confounded/not demonstrable with RTC. https://t.co/RjDvD8m9Sk

[ESMO Open @ESMO_Open]

Osimertinib in aNSCLC harboring different EGFR uncommon variants: RWD from the Italian biomarker ATLAS database in @ESMO_Open. Distinct activity & resistance across variants. ex19delins outcomes similar to classical ex19del. https://t.co/uWZWtjYtNm

[ESMO Open @ESMO_Open]

Efficacy & safety of pembrolizumab–lenvatinib in metastatic endometrial cancer: results from the French multicenter EAP in @ESMO_Open. 351 pts, mPFS 6.0 months, mOS 21 months. Reduced starting lenvatinib dose (n:129) did not impact PFS. https://t.co/6VDo4HBe1s

[ESMO Open @ESMO_Open]

Outcomes of elacestrant in pts with ER+ HER2, ESR1m metastatic breast cancer who received prior ET & CDK4/6 inhibitor in a RW setting in @ESMO_Open.Durable benefit of elacestrant with 8.2 months of mTTNT after 1 to 2 lines of ET+CDK4/6i. https://t.co/p756cGNrxa

[ESMO Open @ESMO_Open]

Safety & efficacy of sotorasib + panitumumab & FOLFIRI for previously treated KRAS G12C-mutated metastatic CRC in the CodeBreaK 101 ph Ib study in @ESMO_Open. 50% G3 or higher TRAEs (mainly skin tox & WBC decrease), ORR 56.5%, mPFS & mOS 8.3 & 17.9 months. https://t.co/QByVTZmG6T

[ESMO Open @ESMO_Open]

HER2DX in early-stage HER2-positive BC: a review of clinical utility in @ESMO_Open. Genomic-clinical test with providing prognostic relapse risk score, pCR score, ERBB2 mRNA expression score. Potential support for individualized Tx discussion. https://t.co/EvAXKNiaGS

[ESMO Open @ESMO_Open]

MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma in @ESMO_Open. MYC-R is poor prognostic marker and refines the double-hit risk model, while gain/amp may be a high risk factor, https://t.co/xQWtbUkLYn

[ESMO Open @ESMO_Open]

Final analysis of the FeDeriCa ph III study: long-term efficacy, safety & PKs of the fixed-dose combination of pertuzumab & trastuzumab for s.c. injection, plus CT in HER2+ early BC in @ESMO_Open. Comparable long-term efficacy, no new safety signals. https://t.co/eFE4MAESrc

[ESMO Open @ESMO_Open]

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02 in @ESMO_Open. irORR 22% and 4% in BTC and PC, respectively, highest in IHC3+ BTC. https://t.co/EIRjrGUUrt

[ESMO Open @ESMO_Open]

Intratumoral Fusobacterium species and survival in resectable colorectal cancer: a multicenter cohort study in @ESMO_Open. Fusobacterium spp presence identifies CRC with aggressive biology, immunesuppression and reduced adjuvant CT benefit. https://t.co/VrwlRrBfea

[ESMO Open @ESMO_Open]

Comparative efficacy of perioperative systemic therapies for MIBC: a network meta-analysis of randomized trials in @ESMO_Open. Improved OS with EV/GC + durva vs GC. Although indirect comparative estimates, EV ranks highest across OS, EFS, and pCR. https://t.co/qQUQ4ZG8X6

[ESMO Open @ESMO_Open]

Superselective intra-arterial CRT for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212 in @ESMO_Open. Reproducible procedure with 3-year OS 68.8%. Prevalent high grade AEs: neutropenia & mucositis. https://t.co/hoHHFjRzCJ

[ESMO Open @ESMO_Open]

Datopotamab-DXd vs CT in previously treated inoperable/metastatic
HR+ HER2- BC: safety & PROs from the ph3 TROPION Breast01 study in @ESMO_Open.Low grade nausea as most common TRAE. Dato-DXd delayed TTD in GHS/QoL, pain & physical functioning. https://t.co/kX9u0h9GoB

[ESMO Open @ESMO_Open]

Somatic BRCA alterations in BC are associated with distinct biological & clinical patterns according to germline BRCA status in @ESMO_Open. Genomic patterns in sBRCA+ depend on germline status. Only gBRCA linked to shorter CDK4/6i therapy TTD. https://t.co/nLWZDDwrn4

[ESMO Open @ESMO_Open]

ERBB2/HER2 landscape & prognostic impact: large-scale, RW analysis across solid cancers in @ESMO_Open. >200,000/80,000 samples for NGS/ IHC. Mut & ampl correlation, with mut associated with higher IHC levels (even w/o ampl). 3+IHC vs 0 = longer survival. https://t.co/cYTwXeA4aB